argenx NV ADR (ARGX)vsEnanta Pharmaceuticals Inc (ENTA)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
ENTA
Enanta Pharmaceuticals Inc
$11.28
-3.84%
HEALTHCARE · Cap: $328.00M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 6752% more annual revenue ($4.74B vs $69.21M). ARGX leads profitability with a 31.4% profit margin vs -89.6%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ENTA
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Margin of Safety
+41.4%
Fair Value
$24.33
Current Price
$11.28
$13.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
15.0% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : ENTA
The strongest argument for ENTA centers on Price/Book, Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ENTA is a turnaround play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.99 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 30/100), backed by strong 31.4% margins and 62.6% revenue growth. ENTA offers better value entry with a 41.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?